Journal of Medical Genetics and Clinical Biology
Homepage : https://journal.antispublisher.id/index.php/JMGCB
Email : admin@antispublisher.com

e-ISSN : 3032-1085
JMGCB, Vol. 2, No. 1, January 2025
Page 53-60

Laboratory Diagnostics of Cervical Cancer

Karimova Aziza Anvarovna[1], Kurbonova Zumrad Chutbayevna[2], Nimatova Mohigul Ilhom Qizi[3], Kurbanova Gavkhar Chutbayevna[4]
[1,2,3,4]Tashkent Medical Academy, Uzbekistan

DOI : https://doi.org/10.61796/jmgcb.v2i1.1081

Sections Info

Article history:
Submitted: December 25, 2024
Final Revised: January 01, 2025
Accepted: January 08, 2025
Published: January 15, 2025

Keywords:
Cervical cancer
Laboratory diagnostics
Human papillomavirus (HPV)
HPV DNA testing
Pap smear
Cytology
Liquid biopsy
Molecular markers
p16INK4A
Ki-67
Artificial intelligence (AI)
Screening
Colposcopy
Visual inspection with acetic acid (VIA)
Early detection
Biomarkers
Circulating tumor DNA (ctDNA)
Exosomes
MicroRNA (miRNA)
Cancer diagnostics
Global health

ABSTRACT

Objective: *This study examines current laboratory diagnostic techniques for cervical cancer, focusing on their application in diverse healthcare settings, with the goal of improving early detection and management.* ***Methods:*** *The research explores various diagnostic methods, including Pap smears, HPV DNA testing, and visual inspection with acetic acid (VIA), alongside advancements such as liquid-based cytology, molecular biomarkers, and artificial intelligence (AI). Comparative analysis highlights their effectiveness, sensitivity, and suitability across resource-diverse contexts.* ***Results:*** *Findings reveal that co-testing with cytology and HPV DNA testing offers superior sensitivity, while molecular diagnostics and liquid biopsy show promise for precision medicine. AI-based tools enhance diagnostic efficiency, particularly in underserved regions. However, challenges in accessibility, cost, and expertise persist in low-resource settings.* ***Novelty:*** *This study underscores the transformative potential of emerging technologies like AI-assisted diagnostics and liquid biopsy, emphasizing their role in bridging healthcare disparities and supporting the World Health Organization's goal of eliminating cervical cancer by 2030.*

INTRODUCTION

Cervical cancer, a leading cause of cancer-related deaths in women, is largely preventable through early detection and appropriate intervention [1], [2]. Advances in medical research and healthcare systems have highlighted the importance of effective screening programs in reducing the burden of this disease [3], [4]. Over the past few decades, the development of reliable laboratory diagnostic techniques has significantly improved the ability to detect precancerous changes and early-stage cervical cancer [5]. These advancements have enabled timely treatment, thereby reducing both morbidity and mortality rates. Despite these achievements, disparities in access to screening and diagnostic tools persist, especially in low-resource settings, posing significant challenges to achieving global cervical cancer control.

The primary cause of cervical cancer is persistent infection with high-risk human papillomavirus (HPV), particularly types HPV-16 and HPV-18 [6], [7]. These HPV types are classified as oncogenic due to their ability to integrate viral DNA into host cells, driving the expression of oncoproteins E6 and E7. These oncoproteins inactivate critical tumor suppressor proteins, such as p53 and Rb, leading to uncontrolled cellular proliferation and eventual malignant transformation. The natural history of HPV infection provides a unique opportunity for intervention; while most HPV infections are transient and resolve spontaneously, persistent infections can progress to cervical intraepithelial neoplasia (CIN) and, over several years, to invasive cancer [8], [9].

Laboratory diagnostic techniques play a pivotal role in identifying precancerous and cancerous changes in the cervix during this window of opportunity. The Papanicolaou (Pap) smear, developed in the mid-20th century, remains a cornerstone of cervical cancer screening programs worldwide. Additionally, the advent of HPV DNA testing has further enhanced diagnostic precision by directly identifying the presence of oncogenic HPV strains. Innovations such as liquid-based cytology (LBC) and co-testing with Pap smears have improved the quality of samples and increased detection rates for high-risk cases [10]. These techniques have transformed the landscape of cervical cancer prevention, particularly in high-income countries where resources support widespread implementation.

However, significant challenges remain in extending these benefits to resource-limited settings, where cervical cancer incidence and mortality are disproportionately high. In these areas, laboratory infrastructure, trained personnel, and affordable diagnostic tools are often lacking. As a result, simpler methods such as visual inspection with acetic acid (VIA) are employed, although they have lower specificity compared to advanced techniques. Emerging technologies, including point-of-care HPV testing and artificial intelligence (AI)-assisted diagnostics, hold promise for bridging this gap. This article provides an overview of the current laboratory diagnostic approaches, explores challenges in implementing these methods in low-resource settings, and examines emerging technologies that aim to improve diagnostic accuracy and accessibility.

RESEARCH METHOD

The Papanicolaou (Pap) smear, developed by Dr. George Papanicolaou in the 1940s, remains one of the most widely used diagnostic methods for the early detection of cervical cancer [11]. This cytological technique involves the collection of cells from the transformation zone of the cervix, which are then examined under a microscope for abnormalities. The Pap smear is effective in detecting precancerous lesions, such as cervical intraepithelial neoplasia (CIN), and early-stage cancer [12], [13]. The introduction of liquid-based cytology (LBC) has improved the quality of Pap smears by reducing the number of inadequate samples and allowing for simultaneous HPV testing [14], [15].

HPV DNA testing is a more sensitive and specific method for detecting high-risk HPV infections that may lead to cervical cancer [16]. This technique involves the

identification of HPV genetic material in cervical cells, providing direct evidence of infection with oncogenic strains of the virus. Two main types of HPV tests are widely used: the hybrid capture 2 (HC2) test and the Cobas 4800 system. These tests identify the presence of high-risk HPV genotypes, and in the case of the Cobas 4800 system, it also detects specific HPV types 16 and 18.

In low-resource settings, where laboratory infrastructure may be inadequate, visual inspection with acetic acid (VIA) is a simple, low-cost alternative for cervical cancer screening. VIA involves applying acetic acid (vinegar) to the cervix and visually inspecting the area for abnormal lesions, which turn white when exposed to acetic acid.

Colposcopy is a key diagnostic tool that allows for the direct visualization of the cervix using a magnifying instrument. When abnormalities are identified, a biopsy is often performed to obtain tissue samples for histopathological examination.

RESULTS AND DISCUSSION

While the Pap smear has been instrumental in reducing cervical cancer incidence in high-income countries, its limitations include variability in sample collection, subjective interpretation, and lower sensitivity in detecting early-stage cancer. Additionally, its effectiveness is dependent on regular screening and follow-up, which can be challenging in resource-limited settings. HPV DNA testing has higher sensitivity than the Pap smear, making it an important tool for primary screening, especially in women over 30, or in combination with cytology (co-testing) for increased accuracy. In some countries, HPV testing has been adopted as the primary screening method, as it offers better early detection of precancerous lesions and reduces the number of false-negative results. However, a positive HPV test does not necessarily mean the presence of cancer, as many HPV infections are transient and resolve spontaneously.

In low-resource settings, VIA has shown reasonable sensitivity in detecting precancerous lesions, but its specificity is relatively low, leading to the possibility of false-positive results. Training and experience are essential for clinicians to accurately interpret the results. Colposcopy and biopsy are critical for confirming the presence and staging of cervical cancer, providing a direct assessment of tissue architecture and grading lesions. However, they are invasive procedures that require specialized training and equipment, making them less accessible in low-resource settings.

Recent advancements in laboratory diagnostics have led to the development of promising new tools and techniques to improve the detection and management of cervical cancer.

a. **Molecular Biomarkers:** The identification of molecular biomarkers that can detect the presence of cervical cancer or predict its progression is an area of intense research. Biomarkers such as p16INK4A, Ki-67, and other molecular markers associated with HPV infection and cervical carcinogenesis may improve the accuracy of diagnostics and help in the management of patients with abnormal screening results.

b. **Liquid Biopsy:** Liquid biopsy, which analyzes circulating tumor DNA or RNA in blood or other bodily fluids, offers a non-invasive alternative to tissue biopsy for diagnosing and monitoring cervical cancer. This approach is still in the experimental stages but holds great promise for early detection, monitoring treatment response, and identifying recurrence.

c. **Artificial Intelligence (AI):** The application of AI in cytology and histopathology has shown potential for improving the accuracy of cervical cancer diagnosis. AI algorithms can assist in analyzing Pap smear slides, HPV test results, and biopsy specimens, reducing human error and increasing diagnostic efficiency. AI-driven tools are being explored to assist in screening programs, particularly in resource-limited settings.

The combination of cytology and HPV DNA testing, known as co-testing, has emerged as a powerful approach for cervical cancer screening. Co-testing offers several advantages over either method used alone. Cytology (Pap smears) is highly effective in identifying cell abnormalities, while HPV testing provides a more direct indication of the risk of persistent infection with high-risk HPV types. This combination enhances the sensitivity of screening, enabling the early detection of precancerous changes or early-stage cancer, particularly in women aged 30 and older.

Co-testing can identify women at high risk of developing cervical cancer who may not exhibit cytological abnormalities but are HPV-positive. Women with negative co-test results can be safely re-screened less frequently, reducing unnecessary follow-up and the risk of overdiagnosis. This approach has been shown to be particularly effective in reducing cervical cancer rates in populations with access to regular screenings.

However, co-testing is more costly and may not be feasible in settings with limited resources. The need for trained personnel to interpret the results and follow up appropriately adds to the logistical complexity. Despite this, co-testing is considered the gold standard in many countries with advanced healthcare systems, offering the best balance of sensitivity and specificity for cervical cancer detection.

The integration of molecular biomarkers into the diagnostic workflow has the potential to revolutionize the detection, prognosis, and management of cervical cancer. Molecular markers can be used to assess the risk of progression from HPV infection to cervical cancer, as well as to identify patients with more aggressive forms of cancer. Some key molecular biomarkers currently under investigation include:

This tumor suppressor protein is often overexpressed in cervical cancer and pre-cancerous lesions, especially in the presence of high-risk HPV types. p16INK4A can be detected through immunohistochemistry, providing a supplementary tool for identifying high-risk lesions, particularly in cases where cytology or HPV testing yields ambiguous results.

This protein is a marker of cellular proliferation, and its expression is elevated in cancerous and precancerous cervical cells. Ki-67, when used in conjunction with other

markers such as p16INK4A, helps identify high-grade lesions that are more likely to progress to invasive cancer.

HPV E6 and E7 oncoproteins play a key role in cervical carcinogenesis. The detection of HPV E6/E7 mRNA in cervical cells is an emerging approach that offers greater specificity in identifying clinically significant infections, as these mRNAs are only expressed in cells with persistent viral integration and carcinogenic potential.

Changes in the DNA methylation pattern of specific genes, such as tumor suppressor genes, are associated with the progression of cervical cancer. DNA methylation tests, although still in the research phase, hold promise as a non-invasive diagnostic tool, particularly for detecting early-stage cancer or monitoring disease recurrence.

The use of molecular biomarkers not only enhances diagnostic accuracy but also allows for personalized treatment approaches, tailoring interventions to the biological behavior of the cancer. However, widespread clinical implementation of molecular diagnostics will require further validation studies and standardized protocols.

Liquid biopsy, which involves the analysis of biomarkers present in bodily fluids such as blood, urine, or cervical secretions, is a rapidly emerging area of research in cervical cancer diagnostics. Liquid biopsies offer several advantages over traditional tissue biopsies, including their non-invasive nature and the ability to obtain real-time information about the tumor's molecular profile.

a. **Circulating Tumor DNA (ctDNA):** ctDNA is fragmented DNA released into the bloodstream by cancer cells. The detection of specific mutations or alterations in ctDNA can provide a powerful tool for diagnosing cervical cancer, monitoring treatment response, and detecting recurrences. Studies have shown that ctDNA analysis may offer sensitivity comparable to tissue biopsies, with the added benefit of being less invasive.
b. **Exosomes and miRNA:** Exosomes, small vesicles secreted by tumor cells, carry molecular information such as microRNA (miRNA) and proteins that reflect the tumor's genetic makeup. Analysis of miRNA profiles from exosomes offers potential for identifying biomarkers specific to cervical cancer. Additionally, the detection of tumor-specific exosomes in cervical secretions or blood could serve as an early diagnostic tool for cervical cancer.

While liquid biopsy shows significant promise in improving diagnostic accuracy and enabling early detection, the technology is still in its nascent stages. Further studies are needed to establish the clinical utility, cost-effectiveness, and standardization of liquid biopsy tests for cervical cancer.

The integration of artificial intelligence (AI) into laboratory diagnostics is transforming the landscape of cervical cancer detection. AI systems, particularly machine learning (ML) algorithms, can assist pathologists and cytologists in analyzing large datasets of images, molecular profiles, and patient histories, providing more accurate and faster diagnoses.

a. **AI in Cytology:** AI-based platforms are being developed to analyze Pap smear slides and liquid-based cytology samples. These platforms use deep learning algorithms to detect abnormal cell patterns with greater accuracy and consistency than human observers, reducing the risk of false-negative and false-positive results. AI models have been trained to recognize subtle cytological changes that may indicate early-stage disease, thereby improving early detection rates.
b. **AI in Colposcopy:** AI-driven analysis of colposcopic images can help clinicians identify areas of concern for biopsy with greater precision. Machine learning algorithms can be trained to detect high-grade lesions, thus enhancing the effectiveness of colposcopy, especially in low-resource settings where trained personnel may be limited.
c. **AI in Histopathology:** AI tools are also being used to assist in the analysis of histopathological slides, where they can identify specific features of cancerous lesions, such as cellular morphology and tissue architecture. These systems can provide pathologists with decision support, ensuring more accurate staging and prognosis determination.

AI technologies have the potential to significantly reduce human error, optimize the use of diagnostic resources, and enable more widespread access to high-quality diagnostic services. However, challenges remain in ensuring the scalability, accessibility, and validation of AI systems, particularly in low- and middle-income countries.

Despite the advancements in laboratory diagnostics for cervical cancer, several challenges remain. One of the main barriers is the limited access to high-quality screening and diagnostic tools in low-resource settings, where the burden of cervical cancer is highest. Efforts to improve access to cost-effective screening methods, such as VIA and HPV testing, are critical to reducing the global incidence of cervical cancer.

Moreover, there is a need for continued research into molecular markers, liquid biopsy technologies, and AI to further improve diagnostic accuracy, early detection, and personalized treatment approaches. The integration of these innovations into global cervical cancer control programs, coupled with efforts to expand access to HPV vaccination and regular screening, will be essential in achieving the World Health Organization's goal of eliminating cervical cancer as a public health problem by 2030.

CONCLUSION

Fundamental Finding : The study underscores that advancements in diagnostic techniques, such as HPV DNA testing, liquid-based cytology, and co-testing, have significantly improved cervical cancer detection, particularly in high-resource settings. These methods demonstrate higher sensitivity and specificity, enabling early intervention. However, disparities in accessibility remain, with resource-limited areas relying on less accurate techniques like VIA. The emerging role of AI, molecular biomarkers, and liquid biopsy technologies further highlights the potential for innovation to bridge gaps in diagnostic accuracy and accessibility. **Implication :** The

findings emphasize the critical need to address global health disparities by ensuring equitable access to advanced diagnostic tools for cervical cancer. Implementing cost-effective and scalable technologies, including AI-assisted diagnostics and molecular biomarker integration, can significantly improve early detection and patient outcomes. These advancements also pave the way for personalized treatment approaches, enhancing the precision of cervical cancer management while reducing mortality rates, particularly in underserved populations. **Limitation :** Despite notable advancements, the research highlights significant limitations, including the variability in diagnostic accuracy across different settings and the high costs associated with advanced technologies. Low-resource settings face challenges in implementing and sustaining these innovations due to inadequate infrastructure, insufficient trained personnel, and limited funding. Additionally, the lack of standardized protocols for emerging technologies, such as liquid biopsy and AI, restricts their widespread adoption and clinical validation. **Future Research :** Future research should focus on developing affordable, scalable, and high-accuracy diagnostic tools tailored for low-resource settings. Efforts should prioritize the validation and integration of molecular biomarkers, liquid biopsy, and AI technologies into routine screening programs. Furthermore, studies exploring the long-term impact of these innovations on global cervical cancer control, particularly in conjunction with HPV vaccination programs, are essential to achieving equitable healthcare outcomes.

REFERENCES

[1] C. A. Burmeister *et al.*, "Cervical cancer therapies: Current challenges and future perspectives," *Tumour Virus Res.*, vol. 13, no. February, 2022, doi: 10.1016/j.tvr.2022.200238.

[2] P. E. Castle, M. H. Einstein, and V. V. Sahasrabuddhe, "Cervical cancer prevention and control in women living with human immunodeficiency virus," *CA. Cancer J. Clin.*, vol. 71, no. 6, pp. 505–526, 2021, doi: 10.3322/caac.21696.

[3] S. J. Curry, T. Byers, and M. Hewitt, *Fulfilling the Potential of Cancer Prevention and Early Detection*. 2004. doi: 10.17226/10941.

[4] A. Sagan, D. Mcdaid, S. Rajan, J. Farrington, and M. Mckee, "Policy Brief Screening," *World Heal. Organ.*, 2020, [Online]. Available: http://www.euro.who.int/en/about-us/partners/

[5] H. Ahmadzadeh Sarhangi, D. Beigifard, E. Farmani, and H. Bolhasani, "Deep learning techniques for cervical cancer diagnosis based on pathology and colposcopy images," *Informatics Med. Unlocked*, vol. 47, no. March, p. 101503, 2024, doi: 10.1016/j.imu.2024.101503.

[6] S. Ramakrishnan, S. Partricia, and G. Mathan, "Overview of high-risk HPV's 16 and 18 infected cervical cancer: Pathogenesis to prevention," *Biomed. Pharmacother.*, vol. 70, no. C, pp. 103–110, 2015, doi: 10.1016/j.biopha.2014.12.041.

[7] D. R. Lowy, D. Solomon, A. Hildesheim, J. T. Schiller, and M. Schiffman, "Human papillomavirus infection and the primary and secondary prevention of cervical cancer," *Cancer*, vol. 113, no. 7, pp. 1980–1993, 2008, doi: 10.1002/cncr.23704.

[8] R. Faridi, A. Zahra, K. Khan, and M. Idrees, "Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer," *Virol. J.*, vol. 8, no. 269, pp. 1–8, 2011.

[9] X. Wang, X. Huang, and Y. Zhang, "Involvement of human papillomaviruses in cervical cancer," *Front. Microbiol.*, vol. 9, no. NOV, pp. 1–14, 2018, doi: 10.3389/fmicb.2018.02896.

[10] D. Geetha, J. Sangeetha, M. L. Malar, and T. V. Kumar, "Comparison of Liquid-Based Cytology and Conventional Pap Smear for Cervical Cancer Screening: a Comprehensive Analysis of Specimen Adequacy, Diagnostic Accuracy, and Clinical Correlation," *Int J Acad Med Pharm*, vol. 6, no. 3, pp. 658–663, 2022, doi: 10.47009/jamp.2024.6.3.134.

[11] I. N. Mammas and D. A. Spandidos, "George N. Papanicolaou (1883-1962): Fifty years after the death of a great doctor, scientist and humanitarian," *J. B.U.ON.*, vol. 17, no. 1, pp. 180–184, 2012.

[12] P. L. Sachan, M. Singh, M. L. Patel, and R. Sachan, "A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation," *Asia-Pacific J. Oncol. Nurs.*, vol. 5, no. 3, pp. 337–341, 2018, doi: 10.4103/apjon.apjon.

[13] F. sadat Najib, M. Hashemi, Z. Shiravani, T. Poordast, S. Sharifi, and E. Askary, "Diagnostic Accuracy of Cervical Pap Smear and Colposcopy in Detecting Premalignant and Malignant Lesions of Cervix," *Indian J. Surg. Oncol.*, vol. 11, no. 3, pp. 453–458, 2020, doi: 10.1007/s13193-020-01118-2.

[14] B. Strander, A. Andersson-Ellström, I. Milsom, T. Rådberg, and W. Ryd, "Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program : a prospective randomized study.," *Cancer*, vol. 111, no. 5, pp. 285–291, 2007, doi: 10.1002/cncr.22953.

[15] J. Zhu *et al.*, "A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer," *Oncol. Rep.*, vol. 18, no. 1, pp. 157–160, 2007, doi: 10.3892/or.18.1.157.

[16] M. G. Dijkstra *et al.*, "Primary hrHPV DNA testing in cervical cancer screening: How to manage screen-positive women? a POBASCAM trial substudy," *Cancer Epidemiol. Biomarkers Prev.*, vol. 23, no. 1, pp. 55–63, 2014, doi: 10.1158/1055-9965.EPI-13-0173.

***Karimova Aziza Anvarovna (Corresponding Author)**
Tashkent Medical Academy, Uzbekistan

Kurbonova Zumrad Chutbayevna
Tashkent Medical Academy, Uzbekistan

Nimatova Mohigul Ilhom Qizi
Tashkent Medical Academy, Uzbekistan

Kurbanova Gavkhar Chutbayevna
Tashkent Medical Academy, Uzbekistan